Limits...
Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.

Parker JC, Burlingame RW, Bunn CC - J Autoimmune Dis (2009)

Bottom Line: There were no significant differences in mean anti-Ro-52 levels in these groups with the exception of that defined by the presence of anti-U1-RNP.Anti-Ro-52 is present throughout the SSc population.The co-existence of anti-Ro-52 with both anti-Ro-60 and anti-aats is confirmed.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Clinical Immunology, Royal Free Hospital, London NW32QG, UK.

ABSTRACT

Background: Antibodies against Ro-52 have been described in patients with a broad spectrum of autoimmune disease, most commonly in association with anti-Ro-60 in systemic lupus erythematosus and Sjogrens syndrome. However, in inflammatory myositis anti-Ro-52 is frequently present without anti-Ro-60 and is closely linked to the presence of aminoacyl-tRNA synthetase (aats) antibodies. To date there have been no comprehensive reports on the frequency of anti-Ro-52 in systemic sclerosis (SSc), a disease characterised by hallmark autoantibodies that occur in non-overlapping subsets. Clinically, each antibody-defined group has a distinct pattern of organ involvement, some featuring myositis.

Objectives: To determine the frequency of anti-Ro-52 in serologically defined groups of SSc patients and to investigate a possible link with myositis-associated autoantibodies.

Methods: Serum samples from 1010 patients with SSc and 55 and 32 patients with anti-aats and anti-Ku respectively were tested for the presence of anti-Ro-52 using a commercial ELISA.

Results: The prevalence of anti-Ro-52 was 15-38% in nine of the eleven sub-groups. There were no significant differences in mean anti-Ro-52 levels in these groups with the exception of that defined by the presence of anti-U1-RNP. In the remaining groups defined by anti-Ro-60 and anti-aats, anti-Ro-52 was present in 92% and 100% respectively. In sera from non-SSc patients with anti-aats, anti-Ro-52 was detected in 64%.

Conclusion: Anti-Ro-52 is present throughout the SSc population. It is neither more prevalent in the myositis-associated antibody groups nor does it segregate with any other major SSc-specific autoantibodies. The co-existence of anti-Ro-52 with both anti-Ro-60 and anti-aats is confirmed.

No MeSH data available.


Related in: MedlinePlus

Anti-Ro-52 levels in 11 serologically defined groups of SSc patients and 2 additional non-SSc groups (anti-aats and anti-Ku antibodies). Boxes show interquartile ranges, lines within the boxes indicate median values and lines outside the boxes indicate maximum and minimum values excluding outliers. (See table 1 for numbers of patients in each group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2654555&req=5

Figure 1: Anti-Ro-52 levels in 11 serologically defined groups of SSc patients and 2 additional non-SSc groups (anti-aats and anti-Ku antibodies). Boxes show interquartile ranges, lines within the boxes indicate median values and lines outside the boxes indicate maximum and minimum values excluding outliers. (See table 1 for numbers of patients in each group).

Mentions: Comparisons of mean anti-Ro-52 values showed the anti-Ro-60 group had significantly higher levels than all other antibody groups except anti-aats – this small group had significantly higher anti-Ro-52 concentrations than all the remaining groups except anti-Ku. There were no significant differences in anti-Ro-52 levels for the rest of the groups (figure 1) apart from with the anti-U1-RNP group which had significantly different levels to the ACA, ATA, ARA, AFA and NDA groups but not the anti-Pm-Scl, anti-Ku and fsnu groups.


Prevalence of antibodies to Ro-52 in a serologically defined population of patients with systemic sclerosis.

Parker JC, Burlingame RW, Bunn CC - J Autoimmune Dis (2009)

Anti-Ro-52 levels in 11 serologically defined groups of SSc patients and 2 additional non-SSc groups (anti-aats and anti-Ku antibodies). Boxes show interquartile ranges, lines within the boxes indicate median values and lines outside the boxes indicate maximum and minimum values excluding outliers. (See table 1 for numbers of patients in each group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2654555&req=5

Figure 1: Anti-Ro-52 levels in 11 serologically defined groups of SSc patients and 2 additional non-SSc groups (anti-aats and anti-Ku antibodies). Boxes show interquartile ranges, lines within the boxes indicate median values and lines outside the boxes indicate maximum and minimum values excluding outliers. (See table 1 for numbers of patients in each group).
Mentions: Comparisons of mean anti-Ro-52 values showed the anti-Ro-60 group had significantly higher levels than all other antibody groups except anti-aats – this small group had significantly higher anti-Ro-52 concentrations than all the remaining groups except anti-Ku. There were no significant differences in anti-Ro-52 levels for the rest of the groups (figure 1) apart from with the anti-U1-RNP group which had significantly different levels to the ACA, ATA, ARA, AFA and NDA groups but not the anti-Pm-Scl, anti-Ku and fsnu groups.

Bottom Line: There were no significant differences in mean anti-Ro-52 levels in these groups with the exception of that defined by the presence of anti-U1-RNP.Anti-Ro-52 is present throughout the SSc population.The co-existence of anti-Ro-52 with both anti-Ro-60 and anti-aats is confirmed.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Clinical Immunology, Royal Free Hospital, London NW32QG, UK.

ABSTRACT

Background: Antibodies against Ro-52 have been described in patients with a broad spectrum of autoimmune disease, most commonly in association with anti-Ro-60 in systemic lupus erythematosus and Sjogrens syndrome. However, in inflammatory myositis anti-Ro-52 is frequently present without anti-Ro-60 and is closely linked to the presence of aminoacyl-tRNA synthetase (aats) antibodies. To date there have been no comprehensive reports on the frequency of anti-Ro-52 in systemic sclerosis (SSc), a disease characterised by hallmark autoantibodies that occur in non-overlapping subsets. Clinically, each antibody-defined group has a distinct pattern of organ involvement, some featuring myositis.

Objectives: To determine the frequency of anti-Ro-52 in serologically defined groups of SSc patients and to investigate a possible link with myositis-associated autoantibodies.

Methods: Serum samples from 1010 patients with SSc and 55 and 32 patients with anti-aats and anti-Ku respectively were tested for the presence of anti-Ro-52 using a commercial ELISA.

Results: The prevalence of anti-Ro-52 was 15-38% in nine of the eleven sub-groups. There were no significant differences in mean anti-Ro-52 levels in these groups with the exception of that defined by the presence of anti-U1-RNP. In the remaining groups defined by anti-Ro-60 and anti-aats, anti-Ro-52 was present in 92% and 100% respectively. In sera from non-SSc patients with anti-aats, anti-Ro-52 was detected in 64%.

Conclusion: Anti-Ro-52 is present throughout the SSc population. It is neither more prevalent in the myositis-associated antibody groups nor does it segregate with any other major SSc-specific autoantibodies. The co-existence of anti-Ro-52 with both anti-Ro-60 and anti-aats is confirmed.

No MeSH data available.


Related in: MedlinePlus